NCT02389309 2026-03-09
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
84 trialsNCT01946529 2026-02-23
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT01087554 2026-01-16
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01187199 2025-10-27
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01326468 2025-09-25
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
Thomas Jefferson University
Phase NA Withdrawn
NCT02420613 2025-04-02
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01529593 2025-03-24
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05773326 2025-02-27
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Recruiting
NCT00838955 2024-07-10
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Loyola University
Phase 2 Terminated
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01614197 2023-07-27
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT02238496 2023-05-25
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Columbia University
Phase 1 Completed
NCT00593060 2023-05-24
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT01611116 2023-05-24
TOR-AML
Goethe University
Phase 2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01827943 2021-05-06
VESTOR
Institut Bergonié
Phase 2 Completed
NCT01065662 2021-04-21
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01687673 2020-12-07
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT02093598 2020-11-27
POEM
MedSIR
Phase 2 Completed
NCT01596140 2020-06-04
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03571438 2020-01-18
COMBOREIN
University Hospital, Grenoble
Phase NA Unknown
NCT01016769 2019-06-26
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT00909831 2019-04-16
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00761644 2019-04-11
Doxil, Bevacizumab and Temsirolimus Trial
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00949325 2019-03-11
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01025453 2018-08-15
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT00022724 2018-06-26
CCI-779 in Treating Patients With Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00784914 2018-04-17
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
Phase 1 Completed
NCT01090466 2018-02-06
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
Cardiff University
Phase 1/2 Completed
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00787969 2018-01-09
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00998036 2017-12-13
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Columbia University
Phase 1 Completed
NCT00610493 2017-12-08
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00775593 2017-11-09
AML1107
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01078142 2017-09-11
BERT
Johannes Gutenberg University Mainz
Phase 1/2 Completed
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01049841 2017-03-10
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00703625 2017-03-07
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
Washington University School of Medicine
Phase 1 Completed
NCT01264341 2017-02-14
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT01204450 2016-12-23
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00921310 2016-12-13
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 1/2 Terminated
NCT01335074 2016-11-15
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Philipps University Marburg
Phase 1/2 Withdrawn
NCT01404104 2016-07-27
Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma
St. Joseph's Healthcare Hamilton
Phase NA Completed